News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2017 Archives

Nov 27, 2017

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29th Annual Healthcare Conference in New York City on Tuesday,...

More
Nov 22, 2017

Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: Stephen Doberstein, Ph.D., has been promoted to Senior Vice President, Research &...

More
Nov 11, 2017
Interim data from the dose-escalation phase of the PIVOT-02 trial highlighted as an oral presentation

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced the first presentation of data from the PIVOT-02 Phase 1/2 Study, which is designed to evaluate the...

More
Nov 10, 2017

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 London Healthcare Conference in London on Wednesday, November 15,...

More
Nov 7, 2017

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2017. Cash and investments in marketable securities at September 30, 2017 were...

More
Nov 7, 2017
Company to host Investor & Analyst Event on Saturday, November 11th following an oral presentation of data from PIVOT Phase 1/2 study of NKTR-214 with nivolumab

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical data will be presented for NKTR-214, Nektar's lead immuno-oncology candidate, a CD122-biased agonist, at the Society for...

More
Nov 7, 2017

Nektar Therapeutics (Nasdaq: NKTR) today announced it is presenting preclinical data on NKTR-358, a potential first-in-class resolution therapeutic that may address the underlying immune system...

More
Oct 31, 2017

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7, 2017, after the close of U.S.-based financial...

More
Sep 21, 2017

Nektar Therapeutics (Nasdaq: NKTR) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer of BioMarin, has been appointed as an independent director to Nektar's...

More
Sep 20, 2017
Clinical Data for NKTR-214 in Combination with Nivolumab Accepted for Oral Presentation (PIVOT-02 Study)

Nektar Therapeutics (Nasdaq: NKTR) today announced that new data across its wholly-owned immuno-oncology (I-O) portfolio will be presented at the upcoming Society for Immunotherapy of Cancer...

More
Sep 12, 2017

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and safety of NKTR-214, the company's lead immuno-oncology...

More
Sep 6, 2017

Nektar Therapeutics (Nasdaq: NKTR) today presented clinical data from the SUMMIT-07 Phase 3 study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain, at the 2017 PAINWeek®...

More
Sep 6, 2017

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan Stanley Global Healthcare Conference in New York...

More
Aug 30, 2017

Nektar Therapeutics (Nasdaq: NKTR) will present clinical data from the SUMMIT-07 Phase 3 efficacy and safety study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain, at the...

More
Aug 8, 2017

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2017. Cash and investments in marketable securities at June 30, 2017 were $310.7...

More
Aug 2, 2017

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017, after the close of U.S.-based financial markets....

More
Jul 18, 2017
NKTR-181 shows significantly less abuse potential compared to oxycodone

Nektar Therapeutics (NASDAQ: NKTR) announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical...

More
Jul 10, 2017

Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate...

More
Jun 6, 2017

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June...

More
Jun 5, 2017

Nektar Therapeutics (Nasdaq: NKTR) today announced that it presented new findings from two Phase 1 clinical studies of NKTR-214, Nektar's lead immuno-oncology candidate, a CD122-biased agonist, at...

More
May 22, 2017

Nektar Therapeutics (NASDAQ: NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research collaboration to explore the combination of...

More
May 18, 2017
New NKTR-214 Data to be Highlighted at ASCO in Poster Presentation and at Investor Event

Nektar Therapeutics (Nasdaq: NKTR) today announced its presence at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated data from clinical...

More
May 15, 2017

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming UBS Global Healthcare Conference on Monday, May 22, 2017 at 1:30 p.m. Eastern...

More
May 9, 2017

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2017. Cash and investments in marketable securities at March 31, 2017 were $362.0...

More
May 3, 2017

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Brian Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program. In this newly-created role, Dr. Kotzin...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide